XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration arrangements and concentration of credit risk - BMS collaboration - Narrative (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Jun. 24, 2021
USD ($)
Dec. 01, 2020
USD ($)
item
Jun. 24, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
item
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Collaboration arrangements                
Number of collaboration targets | item           4    
Revenue       $ 1,989 $ 1,789 $ 466,311 $ 3,428  
Accounts receivable       $ 3,771   $ 3,771   $ 6,618
Enacted tax rate       25.00%   25.00%    
Tax benefit past share issuance cost       $ 0   $ 2,977    
CSL Behring collaboration                
Collaboration arrangements                
Revenue       0 0 462,400 0  
Upfront cash to receive upon the closing of the agreement $ 450,000   $ 450,000          
Other payments received $ 12,400              
Accounts receivable       1,900   1,900   $ 2,100
Regulatory and commercial milestone payments received     $ 1,600,000          
License revenues from related party                
Collaboration arrangements                
Revenue         1,776   3,353  
Collaboration revenues from related party                
Collaboration arrangements                
Revenue         13   75  
Collaboration revenues                
Collaboration arrangements                
Revenue       1,989   3,911    
Collaboration revenues | CSL Behring collaboration                
Collaboration arrangements                
Revenue       500 $ 0 $ 900 $ 0  
BMS arrangement | Bristol Myers Squibb                
Collaboration arrangements                
Initial research term           4 years    
Number of collaboration targets | item   4            
Collaboration Agreement, Threshold Number Of Collaboration Targets That Can Be Replaced | item   2            
Threshold Number Of New Collaboration Targets In The Field Of Cardiovascular Disease | item   2            
License revenue | Bristol Myers Squibb                
Collaboration arrangements                
Revenue       $ 0   $ 0    
Bristol Myers Squibb | BMS arrangement                
Collaboration arrangements                
Collaboration Agreement, Threshold Research, Development And Regulatory Milestone Payments Receivable   $ 217,000